ANI Pharmaceuticals ANIP Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Amneal Pharmaceuticals, Inc.AMRX

$41.46M+26.1%

ViatrisVTRS

$2.02B+10.2%

ALN

Alnylam PharmaceuticalsALNY

$9.15M-16.3%

Eton Pharmaceuticals, Inc.ETON

$3.54M-14.8%

Aurinia PharmaceuticalsAUPH

$945K-92.1%

Zevra Therapeutics, Inc.ZVRA

$2.09M-37.1%

FAQ

What is ANI Pharmaceuticals's other non-current liabilities?

ANI Pharmaceuticals (ANIP) reported other non-current liabilities of $15.54M in Q2 2026.

How has ANI Pharmaceuticals's other non-current liabilities changed year-over-year?

ANI Pharmaceuticals's other non-current liabilities increased by 132.0% year-over-year, from $6.7M to $15.54M.

What is the long-term trend for ANI Pharmaceuticals's other non-current liabilities?

Over 5 years (2020 to 2025), ANI Pharmaceuticals's other non-current liabilities has grown at a -3.4% compound annual growth rate (CAGR), from $14.48M to $12.16M.

What does other non-current liabilities mean?

Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.